Opendata, web and dolomites

CADISS SIGNED

A medical device for the selective dissection of pathological tissues and fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CADISS project word cloud

Explore the words cloud of the CADISS project. It provides you a very rough idea of what is the project "CADISS" about.

either    mesna    2025    least    burden    launch    international    hospital    cagr    save    2016    force    separated    rooms    surgical    company    pathological    damages    people    relying    time    global    expansion    amounting    million    true    critical    carefully    assisted    chemically    cutting    shorter    despite    revolutionary    combines       involve    whereby    150    valued    plane    billion    10    drug    tools    space    9m    surrounding    surgically    auxin    cleavage    difficulties    saves    complications    risk    countries    reducing    attributed    23    pioneer    sub    anesthesia    found    30    health    dissecting    optimal    optimize    surgeon    tearing    undergo    consisting    damaged    dissection    incidence    thereby    weakens    cadiss    topical    surgery    reaching    organ    occupation    mechanical    tissue    market    grow    risks    surgeries    repair    size    minimizing    disease    treatable    hospitals    damage    selective    revenues    diseased    chemical    healthy    replace    remove    period    money    separation    relapse    adhesion    patients    tissues   

Project "CADISS" data sheet

The following table provides information about the project.

Coordinator
AUXIN SURGERY 

Organization address
address: RUE LOUIS DE GEER 6
city: LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AUXIN SURGERY BE (LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Surgery is the art of dissecting tissues in order to repair, remove, or replace a diseased or damaged organ. 30% of the global burden of disease can be attributed to surgically treatable conditions. More than 10% of surgical procedures involve critical dissection steps whereby the pathological tissue is carefully separated from the healthy surrounding tissues. These procedures together have an incidence of 150/100.000 people, amounting for 2 million surgeries per year in developed countries. Despite the importance of selective dissection in surgical procedures, the current tools are sub-optimal because they are all still relying either on tearing force or on non-selective cutting that can damage tissues. Auxin Surgery, a pioneer in novel dissection methods, has found a revolutionary system, CADISS, that combines mechanical force with the topical application of a chemical drug, Mesna that weakens adhesion between tissues thereby facilitating the dissection steps and minimizing the damages to health tissues. CADISS saves time, therefore patients need to undergo anesthesia for shorter period, thereby reducing the risks of complications. Moreover, hospitals save money on the usage of operating rooms and hospital personnel and can optimize the occupation of hospital space. The global general surgery devices market size was valued at over €10 billion in 2016 and is expected to grow at a CAGR of 8.5% by 2025. Chemically assisted dissection can be useful in most surgical procedures consisting in separation of two tissues along a cleavage plane and when at least one of these conditions is true: 1) the risk of relapse is present 2) the risk of side-effects through damage of healthy tissue is present or 3) the risk of facing difficulties for the surgeon is present. CADISS will bring our company to international expansion and growth reaching €23.9M in revenues 3 years after market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CADISS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CADISS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More